Kevin Fitzpatrick, ACC executive vice president and chief innovation officer, has announced that he will be leaving the ACC effective July 17 to become the first CEO of CancerLinQ LLC, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology (ASCO). Kevin will begin this new role on Aug. 3.

Kevin Fitzpatrick

During his seven-year tenure at the College, Kevin has been instrumental in a number of novel partnerships with industry and other stakeholders related to clinical data registry development, patient and physician education campaigns, mobile tool development, and much more. In particular, Kevin has played key roles in the creation and implementation of the Diabetes Collaborative Registry and has been involved in the growth and development of ACC’s PINNACLE Registry.

In his most recent role as ACC’s first chief innovation officer, Kevin has spearheaded the College’s  innovation efforts through his work with health information technology and electronic health record vendors, as well as with 1776 – a DC-based global incubator and seed fund for start-up companies working to address challenges in areas like health care. As an executive vice president of the College, Kevin also shared responsibility for ensuring the ACC’s overall financial health, operational effectiveness and strategic direction.

“There is no doubt that Kevin is leaving a legacy that will continue to benefit the College and its staff well into the future,” said Shal Jacobovitz, ACC CEO. “Kevin’s work establishes a solid foundation to support continued innovation throughout the College.” 

< Back to Listings